HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Data Supplement Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Henley, S.M.D. Articles by Tabrizi, S. J. Search for Related Content PubMed PubMed Citation Articles by Henley, S.M.D. Articles by Tabrizi, S. J. Related Collections MRI Volumetric MRI Huntington's disease

Increased rate of whole-brain atrophy over 6 months in early Huntington disease

From the Dementia Research Centre (S.M.D.H., C.F., N.C.F.), Institute of Neurology, University College London, London, UK; Medical Statistics Unit (C.F.), London School of Hygiene and Tropical Medicine, London, UK; NMR Research Unit (D.G.M.), Institute of Neurology, University College London, UK; Department of Clinical Neurosciences (T.T.W.), Royal Free and University College Medical School, London, UK; Department of Clinical Neurology (N.C.F., S.J.T.), National Hospital for Neurology and Neurosurgery, London, UK; and Department of Neurodegenerative Disease (S.J.T.), Institute of Neurology, University College London, London, UK.

Address correspondence and reprint requests to Dr. Sarah J. Tabrizi, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK; e-mail: s.tabrizi{at}prion.ucl.ac.uk

The authors measured the rate of whole-brain atrophy over 6 months in 13 patients with early Huntington disease (HD) and seven matched controls. Patients with early HD had significantly increased rates of whole-brain atrophy vs controls (mean [SD] HD, 1.10 [0.88]%/year; controls, 0.26 [0.54]%/year). The measurement of cerebral change over short time periods (e.g., 6 months) may be relevant for trials designed to assess effects on neurodegeneration or atrophy.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the August 22 issue to find the title link for this article.

Supported by a UCLH Fast-Track Special Trustees grant, the High Q Foundation, the DoH, the Medical Research Council, and GlaxoSmithKline.

Disclosure: The authors report no conflicts of interest.

Received December 2, 2005. Accepted in final form April 24, 2006.